Value of Knowing and Knowing of Value: the need for an expanded value framework for complementary diagnostics.

Today EPEMED and The Office of Health Economics (OHE) launch their White Paper “The value of knowing and knowing the value: improving health technology assessment of complementary diagnostics”.

Health Technology Assessment of complementary diagnostics: issues, options and opportunities

We are reaching the final phase of the next major initiative led under EPEMED Health Economic Policy and Reimbursement programmatic committee. As you may recall, we launched a collaboration with the Office of Health Economics (OHE) to address current, and future, issues around the Health Technology Assessment (HTA) of complementary diagnostics...

Labs Role In Educating Physicians In Personalised Medicine

Following the 2014 webinar series by the EPEMED Education Committee discussing the “Education and Knowledge Gaps in Personalised Medicine” and the output from dedicated workshops in conjunction with EuroBioForum’s 3rd annual and Diaceutics Convergence meeting, laboratories were identified as having a key role in educating physicians on testing in personalised medicine but remaining an untapped source in the training and educational space.

Health Technology Assessment of Complementary Diagnostics: Issues, Options and Opportunities.

EPEMED Health Economic Policy and Reimbursement programmatic committee is leading our next major initiative. After a year of project planning, the committee is pleased to announce that EPEMED will collaborate with The Office of Health Economics (OHE) to address Health Technology Assessment (HTA) of complementary diagnostics.

Founded in 2009, EPEMED’s consistent focus has been on enhancing patient access to personalised medicine in Europe. Anecdotally, European healthcare systems have been known as variable in providing patients with access to targeted medicines and the tests which inform their selection. However, specific details on the barriers associated with companion products have been lacking, and EPEMED believes that an objective dataset is necessary to inform future policy. Accordingly, in 2012 EPEMED selected La Charité’s leading Institute for Social Medicine, Epidemiology and Health Economics to conduct such a scientific research. The resulting study, titled “Enhancing Patient Access To Pharmaceutical Drug-Diagnostic Companion Products” was conducted from 2012-2014 and released in 2014.

EBE, EFPIA, EPEMED and EDCA believe the Commission Proposal is an important step to ensure a harmonized approach to regulating in-­vitro diagnostic medical devices across the EU...

The clinical utility and medico–economic value of several personalized diagnostic tests has been well described in the literature. Development of such tests, including generation of the necessary supportive clinical validation data...